Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis
Received:06 April 2010
Accepted:25 April 2011
21 December 2017 (online)
Objective: To measure the concentrations of nerve growth factor (NGF) in the synovial fluid from normal dogs and dogs with osteoarthritis (OA) secondary to common joint disorders.
Methods: Nerve growth factor synovial concentrations were measured by ELISA assay in 50 dogs divided into three groups: 12 healthy, 16 affected by acute lameness within seven days before enrolment, and 22 with chronic lameness persisting by more than one month before enrolment and accompanied by radiological signs of OA. Both acute and chronic lameness were secondary to orthopaedic diseases involving the shoulder, elbow and stifle joints. Nerve growth factor synovial concentrations were compared between means for healthy and acute groups and between the three groups using an F-test. Significance level was set at p ±0.05.
Results: Nerve growth factor was detected in all canine synovial fluid samples. However, the mean synovial NGF concentration of healthy dogs (3.65 ± 2.18 pg/ml) was not significantly different from the mean value in dogs with acute lameness (6.45 ± 2.45 pg/ml) (p ± 0.79). Conversely, the mean synovial NGF concentration in dogs with chronic lameness (20.19 ± 17.51 pg/ml) was found to be significantly higher than that found in healthy dogs (p ±0.01).
Clinical significance: This study demonstrates for the first time the presence of NGF in canine synovial fluid and its increased concentrations in dogs with chronic lameness compared to healthy dogs and dogs with acute lameness. The association between chronic lameness and raised synovial concentrations may suggest an involvement of NGF in OA inflammation and chronic pain.
- 1 Johnston SA.. Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract 1997; 27: 699-723.
- 2 Fox SM, Millis D.. Osteoarthritis: the disease. In: Multimodal management of canine osteoarthritis. London: Manson Publishing Ltd; 2010: pg. 24-30.
- 3 Schaible HG, Richter F, Ebersberger A. et al. Joint pain. Exp Brain Res 2009; 196: 153-162.
- 4 Watson JJ, Allen SJ, Dawbarn D.. Targeting nerve growth factor in pain: what is the therapeutic potential?. BioDrugs 2008; 22: 349-359.
- 5 McNamee KE, Burleigh A, Gompels LL.. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain 2010; 149: 386-392.
- 6 Cohen S, Levi Montalcini R, Hamburger V.. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci 1954; 40: 1014-1018.
- 7 Aloe L, Levi-Montalcini R.. The discovery of nerve growth factor and modern neurobiology. Trends Cell Biol 2004; 14: 395-399.
- 8 Fiore M, Chaldakov GN, Aloe L.. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009; 20: 133-145.
- 9 Lewin GR, Ritter AM, Mendell LM.. On the role of nerve growth factor in the development of myelinated receptors. J Neurosci 1992; 12: 1896-1905.
- 10 Levi Montalcini R, Aloe L, Alleva E.. A role for nerve growth factor in nervous, endocrine and immune systems. Prog Neuroendommmmunol 1990; 3: 1-10.
- 11 Levi Montalcini R, Skaper SD, Dal Toso R. et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19: 514-520.
- 12 Skaper SD.. Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions. Mol Neurobiol 2001; 24: 183-199.
- 13 Micera A, Puxeddu I, Aloe L. et al. New insights on the involvement of nerve growth factor in allergic inflammation and fibrosis. Cytokine Growth Factor Rev 2003; 14: 369-374.
- 14 Nockler WA, Renz H.. Neurotrophins in allergic diseases: from neuronal growth factors to intercellular signaling molecules. J Allergy Clin Immunol 2006; 117: 583-589.
- 15 Otten U, Marz P, Heese K. et al. Cytokines and neurotrophins interact in normal and diseased states. Ann NY Acad Sci 2000; 917: 322-330.
- 16 Leon A, Buriani A, Dal Toso R. et al. Mast cells synthesize, store and release nerve growth factor. Proc Natl Acad Sci 1994; 91: 3739-3743.
- 17 Kulka M, Sheen CH, Tancowny BP. et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123: 398-410.
- 18 Bonini S, Rasi G, Bracci-Laudiero ML. et al. Nerve growth factor: neurotrophin or cytokine?. Int Arch Allergy Immunol 2003; 131: 80-84.
- 19 Forsgren S.. New data favouring that neurotrophins are of importance in arthritis. Arthritis Res Ther 2009; 11: 122.
- 20 Seidel MF, Herguijuela M, Forkert R. et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010; 40: 109-126.
- 21 Dicou E, Pierrot S.. Nerve growth factor (NGF) autoantibodies and NGF in synovial fluid: implication in spondylarthropathies. Autoimmunity 1996; 24: 1-9.
- 22 Halliday DA, Zettler C, Robert A.. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 1998; 23: 919-922.
- 23 Aloe L, Manni L, Sebastiani G. et al. Nerve Growth Factor in the synovia of patients with rheumatoid arthritis: correlation with TNF-alpha and IL-1 beta and possible functional significance. Clin Exp Rheumatol 1999; 17: 632-633.
- 24 Iannone F, de Bari C, Dell’Accio F.. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor in human osteoarthritic chondrocytes. Rheumatology 2002; 41: 1413-1418.
- 25 Shelton DL, Zeller J, Ho WH. et al. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005; 116: 8-16.
- 26 Iwakura N, Ohtori S, Orita S. et al. Role of low-affinity nerve growth factor receptor inhibitory antibody in reducing pain behavior and calcitonin gene-related peptide expression in a rat model of wrist joint inflammatory pain. J Hand Surg Am 2010; 35: 267-273.
- 27 Aloe L, Tuveri MA, Carcassi U. et al. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 1992; 35: 351-355.
- 28 Aloe L, Probert L, Kollias G. et al. The synovium of transgenic arthritic mice expressing human necrosis factor contains a high level of nerve growth factor. Growth Factors 1993; 9: 149-155.
- 29 Barthel C, Yeremenko N, Jacobs R. et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther. 2009; 11: R82
- 30 Raychaudhuri SP, Raychaudhuri SK.. The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand J Rheumatol. 2009; 38: 207-215.
- 31 Rihl M, Kruithof E, Barthel C. et al. Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 2005; 64: 1542-1549.
- 32 Manni L, Lundeberg T, Fiorito S. et al. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol. 2003; 21: 617-624.
- 33 Kapoor M, Martel-pelletier J, Lajeunesse D. et al. Role of proinflammatory cytokines in the patho-physiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
- 34 Hegemann N, Wondimu A, Kohn B. et al. Cytokine profile in canine immune-mediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumatol 2005; 18: 67-72.
- 35 Fujita Y, Hara Y, Nezu Y. et al. Proinflammatory cytokine activities, matrix metalloproteinase-3 activity, and sulfated glycosaminoglycan content in synovial fluid of dogs with naturally acquired cranial cruciate ligament rupture. Vet Surg 2006; 35: 369-376.
- 36 Fox SM.. Pathophysiology of osteoarthritic pain. In: Chronic pain in small animal medicine. London: Manson Publishing Ltd; 2010: pg. 74-96.
- 37 Ruiz G, Ceballos D, Banos JE.. Behavioral and histo-logical effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res 2004; 1011: 1-6.
- 38 Marchand F, Jones NG, McMahon SB.. Future treatment strategies for neuropathic pain. Handb Exp Pharmacol 2009; 194: 589-615.
- 39 Pelegrini-da-Silva A, Oliveira MC, Parada CA. et al. Nerve growth factor acts with the beta2–adrenoceptor to induce spontaneous nociceptive behavior during temporomandibular joint inflammatory hyperalgesia. Life Sci 2008; 83: 780-785.
- 40 Comerford EJ, Smith K, Hayashi K.. Update on the aetiopathogenesis of canine cranial cruciate ligament disease. Vet Comp Orthop Traumatol 2011; 24: 91-98.
- 41 Castaneda-Corral G, Jimenez-Andrade JM, Bloom AP. et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience 2011; 178: 196-207.
- 42 Gordon WJ, Conzemius MG, Riedesel E. et al. The relationship between limb function and radio-graphic osteoarthrosis in dogs with stifle osteoarthrosis. Vet Surg 2003; 32: 451-454.